MedPath

Effect of oral tofacitinib and oral methylprednisolone mini-pulse and combination of both in alopecia areata.

Phase 3
Conditions
Health Condition 1: L639- Alopecia areata, unspecified
Registration Number
CTRI/2024/02/063353
Lead Sponsor
Institute of Medical Sciences BH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Clinically diagnosed cases of alopecia areata with severity of alopecia tool (SALT) score of 10 % or over.

2. Age: 18 to 65 years

3. Patients not taking systemic drug in last 1 month and topical treatment in last 15 days.

- All participants who give consent for the study

Exclusion Criteria

1. Patients having history or active tuberculosis.

2. Patients with Pregnancy and lactating mother.

3. Patients with uncontrolled renal, hepatic,

hematological or heart disease.

4. Patients with diabetes mellitus and hypertension.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath